Month: November 2020

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.28020-73-7,2,6-Bis(benzimidazol-2-yl)pyridine,as a common compound, the synthetic route is as follows.

N-butylation of 2,6-bis(benzimidazol-2?-yl)pyridine (bzimpy) was prepared by a reported general N-alkylation method [27]. Bzimpy (1.00 g, 3.2 mM) and NaOH (0.50 g, 12.8 mM) were stirred overnight at 60 ¡ãC. To the stirring solution, 1-bromobutane (1.30 g, 9.6 mM) was added and stirred for two days at 60 ¡ãC. The solvent was then removed on a rotary evaporator to give a white?yellow residue. Chloroform (20 mL) was added to the residue and the precipitated NaBr was removed by filtration. Evaporation of the chloroform yielded a creamy product. Yield: 1.05 g, 78percent (based on bzimpy). Elemental analysis data: Anal. (percent) Calcd forC27H29N5 (423.55): C, 76.56; H, 6.90; N, 16.53. Found (percent): C, 76.28; H, 6.65; N, 16.37. 1H NMR: (CDCl3 as solvent, ppm), 0.71 (t 6H CH3?C), 1.35 (s (sextet) 4H C?CH2?C),4.73 (t 4H C?CH2?C), 1.72 (q (quintet) 4H C?CH2?), 7.37?7.47 (t 4H CH aromatic), 7.89(d 4H CH aromatic), 8.06 (t 1H CH aromatic), 8.33 (d 1H CH aromatic). 13C NMR(CDCl3-d6 as solvent, ppm): 13.48, 19.85, 32.12, 44.64 (aliphatic), 110.39, 120.34, 122.71,123.47, 125.50, 136.31, 138.11, 142.86, 150.57 (aromatic). IR (KBr, nu, cm?1): 2956, 2929,2871, 1434, 1410, 1571, 1328, 1285, 1249, 1178, 1076, 993, 823, 740, 660, 581 cm?1. Mass spect. (ESI): m/z 424 [L]H+ (100percent), 446 [L]Na+ (25percent), 847 [(L)2+H]+ (40percent), 869

28020-73-7, As the paragraph descriping shows that 28020-73-7 is playing an increasingly important role.

Reference£º
Article; Kose, Muhammet; Digrak, Metin; Gonul, Ilyas; McKee, Vickie; Journal of Coordination Chemistry; vol. 67; 10; (2014); p. 1746 – 1759;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

294-90-6, 1,4,7,10-Tetraazacyclododecane is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

To the three-necked flask was added 1,4,7,10-tetraazacyclododecane (100 g, 0.58 mol)10 ml of deionized water, stirred, 30% KOH solution was added dropwise,The pH was adjusted to 8.5 and then chloroacetic acid (263 g, 2.78 mol) was added,And then 30% KOH solution to adjust the pH to 8.5,Heated to 80 C for 24 h, during which the pH was maintained between 8.5 and 9.After the reaction, cooling, adding concentrated hydrochloric acid to adjust the pH to 2, a white precipitate produced, filtered. The filter cake was recrystallized from a water-ethanol solution and the resulting crystals were washed with ethanol, ether, dried,183 g of DOTA crystals was obtained in a yield of 78%.

294-90-6, The synthetic route of 294-90-6 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; Zhejiang Dade Pharmaceutical Group Co., Ltd.; Wang Jianping; Wang Jianguo; (23 pag.)CN104447598; (2017); B;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.2390-68-3,N-Decyl-N,N-dimethyldecan-1-aminium bromide,as a common compound, the synthetic route is as follows.

Didecyldimethylammonium bromide (0.001 mol) was dissolved in 50 mL of hot distilled water. trans-Cinnamic acid (0.001 mol) was added to the didecyldimethylammonium solution. The reaction solution was stirred at 90 C. for 4 h. The reaction solution was cooled to room temperature and then 60 mL of chloroform was added. The two phases were separated and the chloroform phase was washed several times with cool distilled water to remove any inorganic salt. The presence of chloride anions was monitored by silver nitrate test. A rotary evaporator removed the chloroform and a wax was obtained in 93% yield. 1H and 13C NMR (DMSO) were obtained. Melting point (hot plate apparatus)=54-55 C., 2390-68-3

2390-68-3 N-Decyl-N,N-dimethyldecan-1-aminium bromide 16957, acatalyst-ligand compound, is more and more widely used in various fields.

Reference£º
Patent; Rogers, Robin D.; Daly, Daniel T.; Swatloski, Richard P.; Hough, Whitney L.; Davis, James Hilliard; Smiglak, Marcin; Pernak, Juliusz; Spear, Scott K.; US2007/93462; (2007); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

170161-27-0, Tri-tert-butyl 1,4,8,11-tetraazacyclotetradecane-1,4,8-tricarboxylate is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

A suspension of compound 21 (1.59 g), commercially available (Aldrich Chemical Co., Milwaukee, WI) compound 22 (0.8 g) and K2CO3 (0.48 g) in DMF (15 ml) is stirred at 600C overnight. The reaction mixture is concentrated to a thick oil and filtered through a glass syringe filter, dissolved inCH2Cl2 and purified by column chromatography (silica) to give compound 23 (1.96 g)

170161-27-0, The synthetic route of 170161-27-0 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; GLYCOMIMETICS, INC.; MAGNANI, John, L.; SARKAR, Arun, K.; WO2010/126888; (2010); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.137076-54-1,2-(4,7,10-Tris(2-(tert-butoxy)-2-oxoethyl)-1,4,7,10-tetraazacyclododecan-1-yl)acetic acid,as a common compound, the synthetic route is as follows.

A solution of the product of Example 3OB (30.0 mg, 63.8 mumol) and /-Pr2NEt (11 muL, 63 mumol) in dry DMF (1.00 mL) was transferred to a previously prepared solution of (4,7, 10-tris-f¡ãrt-butoxycarbonylmethyl- 1 ,4,7, 10-tetraazacyclododec- 1 – yl)acetic acid (47.5 mg, 82.9 mumol) in DMF (3.00 mL) containing HBTU (26.6 mg, 70.1 mumol), HOBt (10.7 mg, 69.9 mumol) and /-Pr2NEt (44 muL, 0.25 mmol); additional DMF (2 x 0.50 mL) was used to quantitate the transfer. The resulting solution was maintained at 22 C for 3 hours, then concentrated in vacuo and the residue treated with a solution OfEt3SiH in TFA (9:1 v/v, 3.30 mL). After stirring 2.5 hours at 22 0C, the resulting solution was concentrated in vacuo and purified by HPLC on a Phenomenex Luna C18 column (21.2 x 250 mm) using a 0.67%/min gradient of 0- 20% acetonitrile containing 0.1% TFA at a flow rate of 20 rnL/min. The main product peak eluting at 5.5 minutes was lyophilized to a white solid (65.0 mg, 53.6 mumol; 84.0%). MS (ESI): 643.3 (65.2, M+H), 530.3 (36.0), 322.3 (100, M+2H), 265.7 (49.7). HRMS: Calcd for C28H51N8O9: 643.3774; found: 643.3763. The optical purity of the product was established by chiral GLC analysis; 99.8% D- leucine.

137076-54-1, The synthetic route of 137076-54-1 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; BRISTOL-MYERS SQUIBB PHARMA COMPANY; WO2007/5491; (2007); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.787-70-2,[1,1′-Biphenyl]-4,4′-dicarboxylic acid,as a common compound, the synthetic route is as follows.,787-70-2

To a stirred solution of biphenyl-4,4′-dicarboxylic acid (500 mg, 2.06 mmol) in 10 mL of DMF was added N-hydroxysuccinimide (594 mg, 5.16 mmol) and dicyclohexylcarbodiimide (1.06 g, 5.16 mmol) at 0C and the mixture stirred at RT overnight. The reaction mixture was filtered and the filtered cake was washed with EtOAc. The washings and filtrate were combined, washed with brine solution (3×20 mL), dried over anhydrous sodium sulfate and concentrated under reduced pressure to afford a crude product that was dissolved in DCM and again filtered. The DCM layer was concentrated under reduced pressure to afford desired product (600 mg).

As the paragraph descriping shows that 787-70-2 is playing an increasingly important role.

Reference£º
Patent; MEDIVATION TECHNOLOGIES, INC.; RAI, Roopa; PHAM, Son Minh; HART, Barry Patrick; (374 pag.)WO2017/19830; (2017); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.62937-45-5,D-Prolinamide,as a common compound, the synthetic route is as follows.,62937-45-5

[01 1 18] Step 2 : (R)-6-(4-((2-carbamoylpyrrolidin- 1 -yl)methyl)phenyl)- 1 -cyclopentyl-N- ((4,6-dimethyl -2-oxo- 1 ,2-dihydropyridin-3-yl)methy 1)- 1 H-indazole-4-carboxamide [01 1 19] To a stirred solution of 1 -cyclopentyl-N-((4,6-dimethyl-2-oxo- 1 ,2-dihydropyridin- 3-yl)methyl)-6-(4-formylphenyl)-l H-indazole-4-carboxamide (0.175 g, 0.373 mmol) in methanol (3 mL) acetic acid (0.022 g, 0.373 mmol) and respective amine [[[amine quantity?]]] was added, resulting reaction mass was stirred at room temperature for 4 h. To this reaction mixture sodium cyanoborohydride (0.028 g, 0.448 mmol) was added at cooling condition and reaction mixture was stirred at room temperature for 48 h. On completion solvent was removed under reduced pressure and water was added to it, and then extracted with 10% MeOH/DCM. Combined organic layers were washed with water, dried over anhydrous Na2S04, filtered and concentrated under reduced pressure to afford crude. The crude was purified by prep HPLC affording desired compound as TFA salt (12.3% yield). LCMS: 567.30 (M + 1)+; HPLC: 97.31% (@ 254 nm) (R,;5.366); NMR (OMSO-d6, 400 MHz) 6 1 1.52 (s, I H), 9.71 (s, I H), 8.64 (t, I H, J=4.4 Hz), 8.37 (s, IH), 8.17 (s, IH), 7.94- 7.97 (m, 3H), 7.87 (s, IH), 7.61-7.67 (m, 3H), 5.89 (s, lH), 5.31-5.38 (m, I H), 4.38-4.45 (m, 4H), 4.41 -4.13 (m, I H), 3.32 (2H merged in solvent peak), 2.22 (s, 3H), 2.14-2.21 (m, 3H), 2.12 (s, 3H), 1.82-2.08 (m, 7H), 1.70-1.72 (m, 2H).

62937-45-5 D-Prolinamide 447554, acatalyst-ligand compound, is more and more widely used in various fields.

Reference£º
Patent; EPIZYME, INC.; KUNTZ, Kevin, Wayne; OLHAVA, Edward, James; CHESWORTH, Richard; DUNCAN, Kenneth, William; WO2012/118812; (2012); A2;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.92149-07-0,4,7-Dimethoxy-1,10-phenanthroline,as a common compound, the synthetic route is as follows.

92149-07-0, Under an argon atmosphere, add anhydrous Fe(acac)3 (211.8mg, 0.6mmol) to a 50mL Schlenk flask, and dissolve it in 6mL of anhydrous ethanol at 60 C; Then, a solution of 4,7-dimethoxy-1,10-phenanthroline (144.0 mg, 0.6 mmol) in ethanol (4 mL) was added dropwise to the system. The reaction was carried out at 60 C for half an hour, and then returned to room temperature and stirred overnight. The filtrate was collected by filtration, concentrated, washed twice with cold ethanol, and dried under vacuum for 12 h to obtain a red-brown solid product 8 with a yield of 65%.

As the paragraph descriping shows that 92149-07-0 is playing an increasingly important role.

Reference£º
Patent; Chinese Academy Of Sciences Tsingtao Biological Energies And Process Institute; Wang Qinggang; Wang Liang; Zhu Guangqian; Zhang Xianhui; Jing Chuyang; (29 pag.)CN110452272; (2019); A;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

153-94-6, H-D-Trp-OH is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

To a suspension of (R)-2-Amino-3-(lH-indol-3-yl)-propionic acid 2 (0.23 g, 1.12 mmol) (Alfa-Aesar, A- 18426) in acetone (3 mL) was added 2M sodium carbonate (1 mL) to stir at room temperature for 30 minutes. To this mixture was added bromosulfonyl chloride 1 (0.13g, 0.5 mmol) (Alfa-Aesar, A-14677) at 0 0C to stir for 15 minutes. The reaction mixture was stirred further for 1 hour at room temperature. After pouring into water (20 mL), the solution was washed with ether (x3). The aqueous layer was acidified with IM HCl, followed by extraction with ethyl acetate (x3). The combined organic extracts were then washed with brine and dried (Na2SC^) to provide the crude (R)-2-(5-Bromo- thiophene-2-sulfonylamino)-3-(lH-indol-3-yl)-propionic acid product (3) (O.lg, 74 %). LC-MS (ES+) 429, 431; (ES-) 427, 429.A portion of the crude (R)- 2-(5-Bromo-thiophene-2-sulfonylamino)-3-(lH-indol-3-yl)- propionic acid product (3) was taken to the next step without further purification.

153-94-6, The synthetic route of 153-94-6 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; AQUILUS PHARMACEUTICALS, INC; SUCHOLEIKI, Irving; WO2010/75287; (2010); A2;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

99970-84-0,With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.99970-84-0,[2,2′-Bipyridine]-4,4′-dicarbaldehyde,as a common compound, the synthetic route is as follows.

{RuCl(p-cymene)}2(50 mg, 0.08 mmol) and DiPy-G1-MEH (276 mg, 0.16 mmol) were dissolved in distilled DMF (25 mL). The reaction mixture was heated at 80 C. under nitrogen for 4 hours. Then, 2,2′-bipyridine-4,4′-dicarboxaldehyde (Dcbpy) (40 mg, 0.16 mmol) was added and refluxed at 150-160 degrees C. for another 4 hours under reduced light to avoid isomerization (2,2′-bipyridine-4,4′-dicarboxaldehyde was prepared according to the method described in N. Garelli et al, J. Org. Chem. 1992, 57, 3046). Subsequently, an excess of NH4NCS (310 mg, 4.1 mmol) was added to the mixture and heated at 150 C. for a further 4 h. The reaction mixture was cooled to room temperature and the solvent was removed by using a raotary evaporator under vacuum. Water (20 mL) was added to the flask and the insoluble solid was collected on a sintered glass crucible by suction filtration, and washed with distilled water. The crude complex was dissolved on a solution of tetrabutylammonium hydroxide (TBAH) in methanol (5 mL). the concentrated solution was charged onto a Sephadex LH-20 column and eluted with methanol. The main band was collected and concentrated. The required complex was isolated upon addition of 0.01M HNO3.

As the paragraph descriping shows that 99970-84-0 is playing an increasingly important role.

Reference£º
Patent; Isis Innovation Limited; Burn, Paul Leslie; An, Byeong-Kwan; Meredith, Paul; Deceglie, Michael Gardner; US8598350; (2013); B2;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI